1. Merck leaps into COVID vaccine race β€” Evofem Biosciences gets FDA approval for new non-hormonal contraceptive β€” Sanofi sells $13 billion stake in Regeneron β€” See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

NYC Metro Positions for WH

Discussion in 'Allergan' started by anonymous, Nov 24, 2019 at 3:56 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    There are numerous positions posted for Sales Rep and a DM... Any insight?
    Is this for an expansion or did the entire district jump ship?
     

  2. anonymous

    anonymous Guest

    The company has been removing WH reps for years now. It's a dying portfolio, with only LoLo as a bright spot. Don't waste your time bud.
     
  3. anonymous

    anonymous Guest

    they have jumped ship to a different position within company. Same is happening for many others leaving Women Health. Abbvie having a large Women Health salesforce with an underperforming low revenue product is pretty much causing the exodus. It’s good if you are just trying to get by and get some experience...
     
  4. anonymous

    anonymous Guest

    In light of the recently released Global Position Statement by 11 societies in the use of tetsosterone in treating HSDD, will the combined company dust off Intrinsa and/or aquire the Libigel safety data (largest testosterone safety trial with 3656 patients) led by AbbVie's Dr Michael Snabes when he was with Biosante. According to Snabes during the unblinded examinations with 4000 patient years which was over half way through the pre-marketing safety data required by the FDA , they found that restoring T -levels to premenopausal levels reduced cardiovascular events by 70% in menopausal women at risk of experiencing cardiovascular events. It also appears to have reduced breats cancer events by an undisclosed amount. Simply switching compounded and off label Testoterone presently be prescribed to an FDA approved drug should generate over 4 million prescriptions.

    Note: The position statement did not have the benefit of reviewing the Libigel Safety data.

    https://www.menopause.org.au/images/docs/ICMT_A_1637079_O.pdf